These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32043609)

  • 21. Genomic landscape of adenoid cystic carcinoma of the breast.
    Martelotto LG; De Filippo MR; Ng CK; Natrajan R; Fuhrmann L; Cyrta J; Piscuoglio S; Wen HC; Lim RS; Shen R; Schultheis AM; Wen YH; Edelweiss M; Mariani O; Stenman G; Chan TA; Colombo PE; Norton L; Vincent-Salomon A; Reis-Filho JS; Weigelt B
    J Pathol; 2015 Oct; 237(2):179-89. PubMed ID: 26095796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
    Natrajan R; Wilkerson PM; Marchiò C; Piscuoglio S; Ng CK; Wai P; Lambros MB; Samartzis EP; Dedes KJ; Frankum J; Bajrami I; Kopec A; Mackay A; A'hern R; Fenwick K; Kozarewa I; Hakas J; Mitsopoulos C; Hardisson D; Lord CJ; Kumar-Sinha C; Ashworth A; Weigelt B; Sapino A; Chinnaiyan AM; Maher CA; Reis-Filho JS
    J Pathol; 2014 Apr; 232(5):553-65. PubMed ID: 24395524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole exome sequencing of rare aggressive breast cancer histologies.
    Dieci MV; Smutná V; Scott V; Yin G; Xu R; Vielh P; Mathieu MC; Vicier C; Laporte M; Drusch F; Guarneri V; Conte P; Delaloge S; Lacroix L; Fromigué O; André F; Lefebvre C
    Breast Cancer Res Treat; 2016 Feb; 156(1):21-32. PubMed ID: 26907767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H; Cohen AL; Krishnakumar S; Wapnir IL; Veeriah S; Deng G; Coram MA; Piskun CM; Longacre TA; Herrler M; Frimannsson DO; Telli ML; Dirbas FM; Matin AC; Dairkee SH; Larijani B; Glinsky GV; Bild AH; Jeffrey SS
    Breast Cancer Res; 2014 Apr; 16(2):R36. PubMed ID: 24708766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component.
    Avigdor BE; Beierl K; Gocke CD; Zabransky DJ; Cravero K; Kyker-Snowman K; Button B; Chu D; Croessmann S; Cochran RL; Connolly RM; Park BH; Wheelan SJ; Cimino-Mathews A
    Clin Cancer Res; 2017 Aug; 23(16):4875-4884. PubMed ID: 28424200
    [No Abstract]   [Full Text] [Related]  

  • 26. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
    Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
    Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
    [No Abstract]   [Full Text] [Related]  

  • 27. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
    Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
    PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic profiling-based prognostic prediction of patients with advanced small-cell lung cancer in large scale analysis.
    Udagawa H; Umemura S; Murakami I; Mimaki S; Makinoshima H; Ishii G; Miyoshi T; Kirita K; Matsumoto S; Yoh K; Niho S; Tsuchihara K; Goto K
    Lung Cancer; 2018 Dec; 126():182-188. PubMed ID: 30527185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are acinic cell carcinomas of the breast and salivary glands distinct diseases?
    Piscuoglio S; Hodi Z; Katabi N; Guerini-Rocco E; Macedo GS; Ng CK; Edelweiss M; De Mattos-Arruda L; Wen HY; Rakha EA; Ellis IO; Rubin BP; Weigelt B; Reis-Filho JS
    Histopathology; 2015 Oct; 67(4):529-37. PubMed ID: 25688711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
    Pareja F; Selenica P; Brown DN; Sebastiao APM; da Silva EM; Da Cruz Paula A; Del A; Fu L; Weigelt B; Brogi E; Reis-Filho JS; Wen HY
    Histopathology; 2019 Jul; 75(1):139-145. PubMed ID: 30843622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathologic and genetic features of metaplastic breast cancer with osseous differentiation: a series of 6 cases.
    Chao X; Tan W; Tsang JY; Tse GM; Hu J; Li P; Hou J; Li M; He J; Sun P
    Breast Cancer; 2021 Sep; 28(5):1100-1111. PubMed ID: 33942253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
    Mathioudaki A; Ljungström V; Melin M; Arendt ML; Nordin J; Karlsson Å; Murén E; Saksena P; Meadows JRS; Marinescu VD; Sjöblom T; Lindblad-Toh K
    Sci Rep; 2020 Nov; 10(1):19304. PubMed ID: 33168853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.
    Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
    Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
    Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
    Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.
    Tharin Z; Richard C; Derangère V; Ilie A; Arnould L; Ghiringhelli F; Boidot R; Ladoire S
    Sci Rep; 2023 Mar; 13(1):4467. PubMed ID: 36934165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
    López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
    Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.